TQ-1015 is being developed using Securel, TheraQuest’s abuse deterrent technology. TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain.
Najib Babul, CEO of TheraQuest, said: “Sustained release opioids are the standard of care for the management of chronic pain. Unfortunately, it is easy to defeat the sustained release mechanism of such dosage forms, making them subject to drug diversion and drug abuse. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin, thereby minimizing abuse by recreational drug users and drug addicts.”